Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis

Editor Note: For more information about this release, please scroll to bottom.

LONDON, December 15, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Eli Lilly and Company (NYSE: LLY), Nektar Therapeutics (NASDAQ: NKTR), Sanofi (NYSE: SNY), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, December 12, 2014, the NASDAQ Composite ended at 4,653.60, down 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish the day at 17,280.83, and the S&P 500 closed at 2,002.33, down 1.62%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 792.98, down 1.63%, while the index has advanced 7.99% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

On Friday, shares in Zogenix Inc. fluctuated between $1.15 and $1.18 before ending the session 1.71% lower at $1.15. The stock reported a trading volume of 1.56 million shares, below its three months average volume of 1.79 million shares. Zogenix Inc.'s shares have declined 1.71% in the previous three trading sessions, 7.63% in the last one month and 66.57% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $1.25 and $1.87, respectively. Moreover, shares of Zogenix Inc. have a Relative Strength Index (RSI) of 40.50. Sign up and read the free notes on ZGNX at:

http://get.Investor-Edge.com/pdf/?c=Zogenix&d=15-Dec-2014&s=ZGNX

Eli Lilly and Co.'s stock lost 2.88%, to close the day at $69.55. The stock recorded a trading volume of 7.84 million shares, above its three months average volume of 4.49 million shares. The stock oscillated between $69.47 and $71.65 during the session. Over the last one month and over the past three months, Eli Lilly and Co.'s shares have gained 2.76% and 6.56%, respectively. Further, the stock has surged 36.37% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $66.91 is above its 200-day moving average of $62.58. Additionally, Eli Lilly and Co.'s stock traded at a PE ratio of 28.92 and has an RSI of 52.40. The complimentary notes on LLY can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Eli%20Lilly&d=15-Dec-2014&s=LLY

On Friday, shares in Nektar Therapeutics recorded a trading volume of 0.94 million shares, lower than its three months average volume of 1.39 million shares. The stock ended the day at $15.31, which was 1.89% below its previous day's closing of $15.60, and registered an intraday range of $15.27 and $15.60. Nektar Therapeutics' shares have gained 10.43% in the last one month, 10.67% in the previous three months and 34.85% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $14.11 and $12.87, respectively. Furthermore, shares of Nektar Therapeutics have an RSI of 51.53. Register for free on Investor-Edge and access the latest research on NKTR at:

http://get.Investor-Edge.com/pdf/?c=Nektar%20Therapeutics&d=15-Dec-2014&s=NKTR

Sanofi's stock lost 2.27%, to close Friday's session at $45.16, after oscillating between $45.08 and $46.21. The stock recorded a trading volume of 1.86 million shares, below its three months average volume of 2.31 million shares. Over the previous three trading sessions and the last one month, Sanofi's shares have declined 2.34% and 2.94%, respectively. Additionally, from the beginning of 2014, the stock has lost 15.79%. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $52.06 is above its 50-day moving average of $48.87. Further, Sanofi's stock has an RSI of 33.69. The complete research on SNY is available for free at:

http://get.Investor-Edge.com/pdf/?c=Sanofi&d=15-Dec-2014&s=SNY

Novartis AG's stock finished Friday's session 0.87% lower at $93.52. A total of 1.61 million shares were traded, which was above its three months average volume of 1.32 million shares. The stock moved between $93.52 and $94.77 during the session. Novartis AG's shares have fallen by 0.87% in the previous three trading sessions and 0.26% in the last three months. However, the stock has gained 16.35% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $92.26 is greater than its 200-day moving average of $89.17. Novartis AG's stock has an RSI of 44.27. Free in depth research on NVS is available at:

http://get.Investor-Edge.com/pdf/?c=Novartis&d=15-Dec-2014&s=NVS

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.